Stocks and Investing Stocks and Investing
Wed, April 25, 2018

Matthew Harrison Maintained (BIIB) at Buy with Increased Target to $369 on, Apr 25th, 2018


Published on 2024-10-26 04:49:54 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $365 to $369 on, Apr 25th, 2018.

Matthew has made no other calls on BIIB in the last 4 months.



There are 7 other peers that have a rating on BIIB. Out of the 7 peers that are also analyzing BIIB, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Geoff Meacham of "Barclays" Downgraded from Buy to Hold on, Thursday, April 5th, 2018
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $350 on, Wednesday, January 24th, 2018


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Ian Somaiya of "BMO Capital" Maintained at Buy with Decreased Target to $393 on, Monday, March 5th, 2018
  • Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $433 on, Monday, February 5th, 2018
  • Carter Gould of "UBS" Upgraded from Hold to Strong Buy on, Wednesday, January 31st, 2018
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $363 on, Friday, January 26th, 2018
  • Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $400 on, Friday, January 26th, 2018
Contributing Sources